Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately positive: Eight brokerages give Vanda Pharmaceuticals a consensus “Moderate Buy” rating, with five buys, two holds and one sell. The average 12-month price target is $13.70, though recent targets from HC Wainwright and B. Riley were reduced.
• Quarterly results fell short of expectations: Vanda reported an adjusted loss of $1.04 per share versus the expected $0.58 loss, while revenue of $50.53 million missed estimates of $61.92 million. Analysts expect the company to remain unprofitable this fiscal year.
• Institutional ownership remains high: Institutional investors own 88.14% of the stock, with several firms—including Millennium Management and Walleye Capital—substantially increasing their positions. Shares were recently trading near $5.19, well below the 12-month high of $9.94.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $13.70.

Several equities research analysts have issued reports on VNDA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright decreased their price objective on Vanda Pharmaceuticals from $21.00 to $20.00 and set a "buy" rating for the company in a report on Monday. Wall Street Zen downgraded Vanda Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, May 9th. Finally, B. Riley Financial reiterated a "buy" rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in VNDA. Royal Bank of Canada raised its position in Vanda Pharmaceuticals by 34.3% during the first quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company's stock worth $256,000 after acquiring an additional 14,232 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company's stock worth $9,821,000 after acquiring an additional 1,470,898 shares during the period. Hsbc Holdings PLC increased its holdings in shares of Vanda Pharmaceuticals by 17.6% in the second quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company's stock valued at $319,000 after purchasing an additional 9,960 shares during the last quarter. Norges Bank bought a new position in shares of Vanda Pharmaceuticals in the second quarter valued at about $543,000. Finally, Walleye Capital LLC raised its position in shares of Vanda Pharmaceuticals by 155.1% in the second quarter. Walleye Capital LLC now owns 94,298 shares of the biopharmaceutical company's stock valued at $445,000 after purchasing an additional 57,332 shares during the period. Institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Trading Up 5.3%

NASDAQ:VNDA opened at $5.19 on Thursday. The company has a market cap of $313.80 million, a P/E ratio of -1.12 and a beta of 0.64. Vanda Pharmaceuticals has a twelve month low of $4.27 and a twelve month high of $9.94. The business has a 50 day moving average price of $5.71 and a two-hundred day moving average price of $6.69. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.46). The business had revenue of $50.53 million during the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. As a group, analysts expect that Vanda Pharmaceuticals will post -3 EPS for the current fiscal year.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Analyst ratings remain bullish: HC Wainwright maintained a “Buy” rating and a $20 price target, while B. Riley Financial reiterated its “Buy” recommendation. These targets imply significant upside from recent trading levels. B. Riley Financial Reiterates Buy Rating for Vanda Pharmaceuticals
• Positive Sentiment: Psoriasis pipeline visibility: Vanda was included among psoriasis drug stocks to watch during Psoriasis Awareness Month. The company’s potential exposure to psoriasis therapies could provide an additional growth opportunity if its programs advance successfully. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• Neutral Sentiment: Short-interest data shows no meaningful bearish positioning: Reported short interest was zero shares, with a zero-day days-to-cover ratio. However, the reported increase is mathematically invalid because the prior period also showed zero shares, making this data of limited investment value.
• Negative Sentiment: HC Wainwright significantly lowered earnings forecasts: The firm cut its FY2026 EPS estimate to a loss of $3.03 from a loss of $1.98 and reduced its FY2027 estimate to a loss of $0.94 from a loss of $0.36. Quarterly estimates were also lowered across Q3 2026 through Q4 2027, including Q3 2026 EPS of negative $0.61 and Q4 2026 EPS of negative $0.57.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company's research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda's mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda's flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source